ClinicalTrials.gg
CompletedNCT00692055Updated Sep 5, 2008

Study Evaluating the Bioavailability of Naproxen 375 mg in Two Formulations

A Phase 1 interventional study of PN400 and Naproxen in Arthritis, sponsored by POZEN. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2008-09-05.

Sponsored by POZEN (part of Aralez Pharmaceuticals) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 413 studies in Arthritis with a site in United States — 38 open to participants now, 55 under way, 4 of them phase 3. Arthritis · United States.

Enrollment
256th of 337
30 · median 100
Started
2008
with 17 others
Phase 1
29 of 413
4 open now
Registered
90th of 413
by date

Among the 413 studies in Arthritis with a site in United States, this one is the 256th largest by enrollment of the 337 interventional ones that give a count, is one of 18 that started in 2008, is one of 29 in phase 1, and was the 90th registered.

Arthritis

843 studies on the registry are indexed under Arthritis; 118 are open to participants now.

Browse Arthritis studies →

Open to participants now

38 of the 413 studies in Arthritis with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 78 Arthritis studies recruiting now, 41 (53%) set no upper age limit and 20 (26%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 413 studies in Arthritis with a site in United States, or all of them as a file.
02

Study summary

We will evaluate the bioavailability of naproxen 375 mg in two formulations

03

Conditions studied

  • Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or non-pregnant female subjects between 18-55 years as well as other standard inclusion criteria for a study of this nature

Exclusion criteria

Exclusion Criteria:

  • Standard exclusion criteria for a study of this nature
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    1

    PN400

    Drug: PN400

  • Active comparator
    2

    naproxen 375 mg

    Drug: Naproxen

Interventions

06

What researchers measure

Primary outcomes

  1. To assess and compare the pharmacokinetics bioavailability of a single oral dose of naproxen administered in two formulations

    Time frame: 72-hour PK

Secondary outcomes

  1. To evaluate the safety of the two treatments

    Time frame: entire study duration

07

Study locations

1 site
  • Austin, Texas, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2008
First posted
Jun 6, 2008
Start
Jun 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Last update
Sep 5, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00692055
Lead sponsor
POZEN
First posted
Jun 6, 2008
Start date
Jun 2008
Primary completion
Jul 2008
Completion
Jul 2008
Last update
Sep 5, 2008

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naproxen · Esomeprazole

Start the discussion